| Identification | Back Directory | [Name]
L-Glutamic acid, N-[[[(1R)-1-carboxy-2-[[(4-fluorophenyl)methyl]thio]ethyl]amino]carbonyl]- | [CAS]
564482-79-7 | [Synonyms]
DCFBC
L-Glutamic acid, N-[[[(1R)-1-carboxy-2-[[(4-fluorophenyl)methyl]thio]ethyl]amino]carbonyl]- | [Molecular Formula]
C16H19FN2O7S | [MOL File]
564482-79-7.mol | [Molecular Weight]
402.39 |
| Hazard Information | Back Directory | [Uses]
DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor that can be used for small animal positron emission tomography (PET) imaging. DCFBC labeled with F18 ([18F]DCFBC) can images in severe combined immunodeficient mice. [18F]DCFBC uptake is higher in PIP tumors, but almost absent in FLU tumors. [18F]DCFBC uptake is also high in the kidney and bladder, but the radioactivity washout time is shorter than that in PIP tumors. Indicating that [18F]DCFBC can specifically localize to PSMA+ expressing tumors and is applicable to the study of prostate cancer[1]. | [References]
[1] Mease RC, et al. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008 May 15;14(10):3036-43. DOI:10.1158/1078-0432.CCR-07-1517 |
|
|